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≤ 30% or with unprotected left main/last patent conduit and LV ejection fraction ≤ 35%
during PCI. Patients were randomized to either intra aortic balloon pump (IABP) or
Impella (Abiomed). The primary endpoint was a composite of ten major adverse events
(MAE) measured at 30 and 90 days. Economic analyses were performed to assess
resource utilization for patients treated with Impella compared to IABP from index
stay up to 90 days. Itemized hospital bills were collected for U.S. patients that
consented for the economic study (N=260), converted to costs using department level
cost-to-charge ratios, and modeled for the complete trial patient population at 90 days.
Estimated costs were validated via comparison with MedPAR. Measures of episode-
of-care costs, major adverse cardiac and cerebral events (MACCE), and
Quality-Adjusted Life Years (QALYs) for both study arms served as inputs to a Markov
model to estimate the incremental cost-effectiveness ratio (ICER).
Results: MAE at 90 days for Impella were 40.8% vs. IABP 51.4% (p=0.029) including
a 51% relative reduction in repeat revascularization (Impella 6.1% vs. IABP 12.4%,
p=0.026). For the economic study, index hospital costs were lower in the IABP arm
while readmission costs and length of stay were lower in the Impella arm. Median
hospital days for entire episode-of-care for Impella were 7 days vs. IABP 9 days
(p=0.048). Reduction in MAE was associated with a gain in QALY for Impella patients.
Base case ICER was well below the $100,000 value often given as a threshold for
innovative technologies.
Conclusion: For patients with severe LV dysfunction and complex anatomy,
prophylactic use of Impella during PCI reduced MAE at an incremental cost per
quality-adjusted life year considered to be cost-effective for advanced cardiovascular
technologies. Reductions in repeat revascularizations, readmission costs and length of
stay may have significant health policy implications.
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Background: Ventricular fibrillation (VF) may happen during complex coronary
intervention due to wire or catheter manipulation, balloon inflation or reaction to the
contrast. This can be treated easily with prompt cardioversion; however some of VF
may become refractory especially in the cases of severe ischemic burden, elevated left
ventricular filling pressure (LVEDP) or reduced left ventricular function.
Methods: We report a new simple quick method to reduce LVEDP by inserting a
catheter (e.g a pigtail or JR) inside the left ventricle (LV) and doing quick manual
aspiration of 80-100cc of blood from the LV cavity. This will quickly reduce the
LVEDP and make refractory VF easily responsive to cardio version. It can also provide
a simple decompression of the overfilled LV after prolonged circulatory arrest.
Results: This method was used in 8 cases of refractory VF. Five of them failed 3
attempts of DC cardioversion despite recanulization of the diseased artery. After doing
this maneuver, those five cases responded immediately to the next attempt of
cardioversion. Three other cases of VF responded to cardioversion with electrical sinus
rhythm however the 3 patients remained pulseless in electromechanical dissociation
(EMD), no arterial pressure and no cardiac movement on fluoroscopy. Despite ruling
out tamponade and mechanically treating cardiac ischemia the two patients remained
in EMD. After doing the pigtail maneuver EMD resolved and active cardiac movement
were seen on fluoroscopy with acceptable arterial pressure recovery. All of these 8
patients survived till hospital discharge.
Conclusion: Quick insertion of a catheter in the LV with quick blood aspiration
facilitates response to cardioverion and may relief EMD not related to tamponade
during coronary intervention. It looks that the interventional cardiologists need this
simple way of LV venting in the cath lab.
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Background: Background: Coronary artery disease (CAD) is the cause of Ventricular
Dysfunction and Heart Failure (HF) in the majority of patients (pts), and HF is the
only mode of CAD presentation associated with increasing incidence and mortality.
Among a large number of patients there is no evidence about witch therapeutic strategy
is better, so a large number of patients how could be beneficiated by a Coronary
Angioplasty with Stent (PCI) receive medical treatment.
Methods: Methods: Between June 2005 and December 2010 we performed 3450
consecutives coronary angiographies, among those pts 255 (7.4%) have had
LVEF<35% and coronary disease. We divide the pts en 2 groups: MT and PCI.
Results: Results: population: age 66.8 ± 9.4 years, 84% male, 80.3% hypertension,
35.2% diabetes, 72.9% lipid disorders, 12.8% smokers, 55.6% ex-smokers, 26.5% with
familiar history of CAD, 62.3% with previous AMI, 3.1 % previous Stroke, 15.2%
previous PCI and 25.6% previous CABG. One out of 5 pts were hospitalized in the
last year because of HF. At baseline 46.6% of the pts were in dyspnea FC III-IV; 11.2%
in FC I-II and 42.2% were asymptomatics. Only 54 % of the total population received
complete Medial Treatment (MT) (bet blockers, enalapril and diuretics). Multivesel
disease was present in 55.8% of the pts. CABG were performed in 28 pts (10.9%), PCI
in 135 pts (52.9%), in 65 pts a MV PCI was performed. Drug eluting stents (DES)
were used in 63.2% of PCI. The others 92 pts (36.1%) continues with MT. Twelve (12)
pts received definitive pace-maker and 10 pts. ICD. Total mortality was 13.5%, no
significant differences were found among groups. At follow-up pts who underwent
PCI showed an statistically significant diminution in dyspnea FC from III-IV to I-II
and other symptoms (FC I-II 21.7% vs. 66.0% post PCI, p<0.0001 and FC III-IV 73.3%
vs. 7.6% post PCI, p<0.0001, asymptomatics 5.0% vs. 26.4 at F/U, p 0.002) compared
with MT group pts (FC I-II 0% vs. 17.9%, p- y FC III-IV 13.9% vs. 7.7% at FU, p
0.37; asymptomatics 86.1% vs. 74.4% at F/U, p 0.18). In the CABG group
asymptomatics pts were 69.2% pre CABG and 63.6% at FU, p 0.8.
Conclusion: Conclusion: in pts with severe left ventricular dysfunction (LVEF <35%)
and CAD, PCI improved symptoms and there after quality of life and don’t increase
mortally at long term Follow up.
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Background: Randomized studies suggest that intracoronary transplantation of
autologous cells may improve Left Ventricular Ejection Fraction (LVEF) in heart
failure (HF).
Methods: 77 patients were enrolled and completed 5 years follow up. Patients
underwent SPECT evaluation; all had LVEF ≤ 25%, 40 patients with isquemic HF
(IHF) and 37 patients with non-isquemic HF (nIHF). For IHF and nIHF at baseline:
the median age was 67 and 64 years old respectively (ns); NYHA III/IV were 31/9 and
29/8 respectively (ns); median LVEF were 18.7% and 24.7% respectively (ns); median
EDV were 281 ml and 242 ml respectively (p=0.16, ns) and median ESV were 217 ml
and 189 ml respectively (p=0.29, ns). Median numbers of MNC & CD34+ cells were
12*108 & 23*106 respectively. Cells were delivered in 90 cc using a retrograde
technique by coronary sinus approach using a balloon occlusion “over wire” for 10 to
15 minutes. No early or late study related adverse events were observed.
Results: After a median time of 21 days, patients in both groups had relief of dyspnea
symptoms and improvement in functional class. All patients were evaluable at one year
and 32 and 30 in each group for 5 years follow-up. Differences (Δ) and statistic
difference (p) are shown in the table:
Results
Conclusion: Infusion of autologous bone marrow cells into the coronary vein is safe
and feasible. It is associated with significant improvement in symptoms and functional
capacity benefit. Both groups benefited in terms of LVEF improvement and lower ESV.
Our data suggest that nIHF patients have a higher LVEF increment than IHF patient
and lasting up to 5 years; revealing a high restoration of myocardial dysfunction.
Further randomized studies are warranted.
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